In immunology, the effectiveness of a vaccine is often measured by the "magnitude" of the response—how many antibodies or T cells are produced. However, the "flavor" of that response, known as immune polarization, is frequently more important than the quantity. The immune system typically branches into two primary functional states: Th1 (cellular/pro-inflammatory) and Th2 (humoral/anti-inflammatory).
For pathogens that hide inside host cells, a Th2-biased response is often a failure of strategy. This research direction explores how to engineer vaccines and adjuvants that force the immune system into a Th1-biased state to clear intracellular threats like viruses, tumors, and sequestered bacteria.
The Functional Divide
The Th1/Th2 paradigm represents a strategic choice by the adaptive immune system. A Th2-biased response prioritizes the production of neutralizing antibodies (humoral immunity) and cytokines like IL-4 and IL-6. As Zhao et al. demonstrate in the context of Enterovirus 71, this is highly effective for clearing pathogens circulating freely in the blood.
However, many of the most difficult-to-treat diseases involve pathogens that reside within host cells, such as Brucella or Leishmania. These "hidden" reservoirs are physically shielded from antibodies. To clear them, the body requires a Th1-biased response, characterized by the production of Interferon-gamma (IFN-γ) and the activation of macrophages. Li et al. argue that this cellular arm is the only way to destroy bacteria sequestered within macrophages. Without this specific polarization, the immune system may produce a high volume of antibodies that are essentially "shooting at ghosts" while the infection persists internally.
Engineering the Skew
Researchers use three primary levers to steer the immune system toward a Th1 profile: genetic attenuation, adjuvant selection, and delivery platforms.
1. Genetic Deletion
By removing specific viral proteins that interfere with host signaling, researchers can "unmask" the pathogen to the Th1 pathway. For example, Hu et al. showed that deleting the G protein from Respiratory Syncytial Virus (RSV) shifts the host response from a dangerous Th2-bias to a safer Th1-bias. This is critical because a Th2 skew in RSV is associated with vaccine-enhanced respiratory disease, whereas a Th1 skew ensures safe viral clearance. Similarly, Jentarra et al. found that mutating the E3L gene in Vaccinia virus significantly attenuates the virus while maintaining a potent Th1-dominated response.
2. Targeted Adjuvants
Adjuvants act as a compass for the immune system. Traditional adjuvants like alum often favor Th2 responses, which Sun et al. note is often insufficient for cancer immunotherapy. To fix this, researchers are developing "Th1-polarizing" adjuvants:
- TLR9 Agonists: Castiglioni et al. utilized TLR9 agonists to prevent the inflammatory cytokine storms caused by viral endosymbionts in Leishmania.
- RIG-I Agonists: Bai et al. introduced dsRNA-based adjuvants that target the RIG-I receptor, significantly boosting IFN-γ secretion and T-cell mediated immunity for COVID-19 vaccines.
- Synergistic Combinations: Hernandez‐Davies et al. developed the IVAX-1 formulation, which combines multiple pathways to induce a broad, Th1-skewed response that improves cross-reactivity against influenza variants.
3. Platform Geometry
The physical structure of the vaccine itself matters. Yang et al. demonstrated that a core-shell structured mRNA vaccine elicits a strong Th1-biased response, evidenced by a high ratio of IgG2 to IgG1 antibodies—a classic molecular signature of Th1 polarization in murine models.
Overcoming Biological Resistance
A major challenge in this field is that the human body sometimes has a natural "anti-Th1" bias due to environmental or physiological factors.
Pregnancy is a naturally Th2-dominant state designed to prevent the mother's immune system from attacking the fetus. However, Lu et al. explain that this anti-inflammatory environment suppresses the Th1 response needed to control viruses like Hepatitis B, creating a permissive environment for viral replication.
Similarly, helminth (parasitic worm) infections are common in many parts of the world and aggressively push the host toward a Th2 state. Barry et al. highlight that this biological interference can actively suppress the pro-inflammatory Th1 response required for viral vector vaccines (like those for Ebola) to be effective.
Why It Works: The Quality of Help
The ultimate goal of Th1 polarization is often to provide better "help" to other parts of the immune system. Mosmann et al. and the authors of the HVTN 106 trial found that the quality of the T cell response—specifically the presence of rare cytokine-producing subsets—is a better predictor of vaccine success than the total number of cells. By steering the immune response toward a Th1-biased profile, researchers aren't just increasing the volume of the immune system; they are tuning its frequency to ensure that the cellular and humoral arms work in synergy to eliminate the most elusive pathogens.
Key Foundational Work
CpG oligodinucleotides induce strong humoral and cellular responses to swine streptococcic septicemia vaccine in piglets in vivo (2005) — contributed 2 concept elements to this direction.
Vaccinia viruses with mutations in the E3L gene as potential replication-competent, attenuated vaccines: Scarification vaccination (2008) — contributed 1 concept elements to this direction.